Influence of acetylator phenotype on the haematological and biochemical effects associated with dapsone in leprosy patients

Leprosy Review

Volumn 68, Issue 3, 1997, Pages 212-217

  Queiroz, R H C ^a   Souza, A M ^a   Melchior, E ^a   Gouveia, E G ^a   Carvalho, D ^a  

^a Fac Pharmaceutical Sci of S Paulo   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

DAPSONE; LEPROSTATIC AGENT;

ACETYLATOR PHENOTYPE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACETYLATION; FEMALE; HEMOLYTIC ANEMIA; HUMAN; LEPROSY; MALE; METHEMOGLOBINEMIA;

EID: 0030694450     PISSN: 03057518     EISSN: None     Source Type: Journal    
DOI: 10.5935/0305-7518.19970029     Document Type: Article

References (19)

1. Evans, DAP. Acetylation. In Ethnic differences in reactions to drugs and xenobiotics, eds Kalow, W., Goedde, H.W. & Agarwal, D.P., New York: Alan R. Liss, Inc., 1986: pp. 209-242.
2. Ilett, KF, Chiswell, GM, Spargo, RM, Platt, E, Michin, RF. Acetylation phenotype and genotype in aboriginal leprosy patients from the north-west region of Western Australia. Pharmacogenetics, 1993; 3:264-269.
3. Hayes, RB, Bi, W. Rothman, N, Bioly, F, Caporaso, N, Feng, P, Yow, X, Yim, S, Woosley, RL, Meyer, UA. N-acetylation phenotype and genotype and risk of bladder cancer in benzidine-exposed workers. Carcinogenesis, 1993; 14:675-678.
4. Reidenberg, MM, Drayer, DE, Lorenzo, B, Strom, BL, West, SL, Snyder, ES, Freundlich, B, Stolley, PD. Acetylation phenotypes and environmental chemical exposure of people with idiopathic systemic lupus erythematosus. Arthritis Rheum, 1993; 36:971-973.
5. Ong, ML, Mant, TG, Veerapen, K, Fitzgerald, D, Wang, F, Manivasagar, M, Bosco, JJ. The lack of relationship between acetylator phenotype and idiopathic systemic lupus erythematosus in a South-east Asian population: a study of Indians, Malays and Malaysian Chinese. Br J Rheumatol, 1990; 26:462-464.
6. 2 genotype in chinese males. Pharmacogenetics, 1993; 3:250-255.
7. Vandher, A, Lalljee, M. Patient treatment compliance in leprosy - A critical review. Int J Lepr, 1992; 60:587-607.
8. Bruce-Chwatt, LJ. Essential malariology. Heinemann, London, 1982: pp. 181-182.
9. Gallant, JE, Moore, RD, Chaisson, RE. Prophylaxis for opportunistic infections in patients with HIV infections. Ann Intern Med, 1994; 120:932-944.
10. Coleman, MD. Dapsone: modes of action toxicity and possible strategies for increasing patient tolerance. Brit J Dermatol, 1993; 129:507-513.
11. Coleman, MD. Dapsone toxicity: some current perspectives. Gen Pharmac, 1995; 26:1461-1467.
12. Zuidema, J, Hilbers-Modderman, ESM, Merkus, FWHM. Clinical pharmacokinetics of dapsone. Clin Pharmacok, 1986; 11:299-315.
13. Rieder, MJ, Shear, NH, Kanee, A, Tang, BK, Spielberg, SP. Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions. Clin Pharmacol Ther, 1991; 49:13-17.
14. Reidenberg, MM, Drayer, D, De Marco, AL, Bello, CT. Hydraiazine elimination in man. Clin Pharmac Ther, 1973; 17:722-730.
15. Lohr, GW, Waller, HD. Glucose-6-phosphate dehydrogenase. In Methods of enzymatic analysis. HU Bergmeyer, Editor, Academic Press, New York, 1974: pp. 636.
16. Kelly, C, Griffiths, ID. Dapsone in rheumatoid arthritis. Ann Rheum Dis, 1981; 40:630.
17. Gill, HJ, Tingle, MD, Park, BK. N-hydroxylation of dapsone by dapsone enzymes of cytochrome P450: implications for inhibition of haematoxicity. Br J Clin Pharmacol, 1995; 40:531-538.
18. Byrd, SR, Gilber, RH. Effect of dapsone on haemoglobin concentration in patients with leprosy. Lepr Rev, 1991, 62:171-178.
19. Rhodes, LE, Tingle, MD, Park, BK, Chu, P, Verbov, JL, Friedmann, PS. Cimetidine improves the therapeutic/toxic ratio of dapsone in patients on chronic dapsone therapy. Brit J Dermatol, 1995; 132:257-262.